Skip to main content
SpringerLink
Log in

Neuromuscular Emergencies

  • Chapter
  • First Online:
Emergencies in Neurology

  • 628 Accesses

Abstract

A conscious patient presenting to the emergency with sudden or relatively rapid onset of weakness should raise the suspicion of a disorder affecting the motor unit, in addition to the other parts of the neuraxis. The various neuromuscular disorders with such presentations can be categorized into disorders affecting the nerve roots, peripheral nerves, neuromuscular junction or the muscle.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Hartung HP, Pollard J, Harvey G, et al. Immunopathogenesis and treatment of the Guillain–Barré syndrome. Part 2. Muscle Nerve. 1995;18:154–64.

    Article  CAS  Google Scholar 

  2. van der Meche FGA, Schmitz PIM. The Dutch Guillain–Barré study group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain–Barré syndrome. N Engl J Med. 1992;326:1123–9.

    Article  Google Scholar 

  3. Winer JB, Hughes RAC, Anderson MJ, et al. A prospective study of acute idiopathic neuropathy. Antecedentevents. J Neurol Neurosurg Psychiatry. 1988;51:613–8.

    Article  CAS  Google Scholar 

  4. Steininger C, Seiser A, Gueler N, et al. Primary cytomegalovirus infection in patients with Guillain–Barré syndrome. J Neuroimmunol. 2007;183:214–9.

    Article  CAS  Google Scholar 

  5. Orlikowski D, Quijano-Roy S, Sivadon-Tardy V, et al. Campylobacter jejuni and cyto-megalovirus (CMV) infections in patients with the Guillain–Barré syndrome. Arch Pediatr. 2006;13:1561–5.

    Article  CAS  Google Scholar 

  6. Visser LH, van der Meche FG, Meulstee J, et al. Cytomegalovirus infection and Guillain–Barré syndrome: the clinical, electrophysiologic, and prognostic features. Neurology. 1996;47:668–73.

    Article  CAS  Google Scholar 

  7. Johnson NT, Crawford SW, Sargur M. Acute acquired demyelinating polyneuropathy with respiratory failure following high dose systemic cytosine arabinoside and marrow transplantation. Bone Marrow Transplant. 1987;2:203–7.

    CAS  PubMed  Google Scholar 

  8. Eliashiv S, Brenner T, Abramsky O, et al. Acute inflammatory demyelinating polyneuropathy following bone marrow transplantation. Bone Marrow Transplant. 1991;8:315–7.

    CAS  PubMed  Google Scholar 

  9. Drachman DA, Paterson PY, Berlin BS, et al. Immunosuppression and the Guillain–Barré syndrome. Arch Neurol. 1970;23:385–93.

    Article  CAS  Google Scholar 

  10. Feasby TE. Inflammatory demyelinating polyneuropathies. Neurol Clin. 1992;10:651–70.

    Article  CAS  Google Scholar 

  11. Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain–Barré syndrome. Ann Neurol. 2010;67:781–7.

    PubMed  Google Scholar 

  12. Sharshar T, Chevret S, Bourdain F, et al. Early predictors of mechanical ventilation in Guillain–Barrésyndrome. Crit Care Med. 2003;31:278–83.

    Article  Google Scholar 

  13. Barohn R, Kissel JT, Warmolts JR, et al. Chronic inflammatory polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol. 1989;46:878–84.

    Article  CAS  Google Scholar 

  14. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain–Barré syndrome. Ann Neurol. 1990;27:S21.

    Article  Google Scholar 

  15. Grand’Maison F, Feasby TE, Hahn AF, et al. Recurrent Guillain–Barré syndrome: clinical and laboratory features. Brain. 1992;115:1093.

    Article  Google Scholar 

  16. Albers JW, Kelly JJ. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve. 1989;12:435.

    Article  CAS  Google Scholar 

  17. Zweig MH, Adornato B, Van Steirteghem AC, et al. Serum creatine kinase BB and MM concentrations determined by radioimmunoassay in neuromuscular disorders. Ann Neurol. 1980;7:324–8.

    Article  CAS  Google Scholar 

  18. Plasma Exchange/Sandoglobulin Guillain–Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain–Barré syndrome. Lancet. 1997;349:225–30.

    Article  Google Scholar 

  19. French Cooperative Group on Plasma Exchange in Guillain–Barré Syndrome. Appropriate number of plasma exchanges in Guillain–Barré syndrome. Ann Neurol. 1997;41:298–306.

    Article  Google Scholar 

  20. Guillain–Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methyl-prednisolone in Guillain–Barré syndrome. Lancet. 1993;341:586–90.

    Google Scholar 

  21. Hughes RA, Swan AV, Raphel JC, et al. Immunotherapy for Guillain–Barré syndrome: a systematic review. Brain. 2007;130:2245–57.

    Article  Google Scholar 

  22. Lawn ND, Fletcher DD, Henderson RD, et al. Anticipating mechanical ventilation in Guillain–Barré syndrome. Arch Neurol. 2001;58:893–8.

    Article  CAS  Google Scholar 

  23. Wolinsky JS, Cornblath D. The North American study of plasmapheresis in the Guillain–Barré syndrome: The Guillain–Barré syndrome Study Group. J Clin Apher. 1985;2:315–20.

    Article  Google Scholar 

  24. McKhann GM, Griffin JW, Cornblath DR, et al. Plasmapheresis and Guillain–Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol. 1988;23:347–53.

    Article  CAS  Google Scholar 

  25. Thomas CE, Mayer SA, Gungor Y, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology. 1997;48:1253–60.

    Article  CAS  Google Scholar 

  26. Grover KM, Sripathi N, Schultz L, et al. Correlation of autoantibodies in myasthenia gravis with phenotypic presentation and disease severity. Ann Neurol. 2008;64(Suppl 12):S6.

    Google Scholar 

  27. Berroushot J, Baumann I, Kalishewski P, et al. Therapy of myasthenic crisis. Crit Care Med. 1997;25:1228–35.

    Article  Google Scholar 

  28. Bershad EM, Feen ES, Suarez JI. Myasthenia gravis crisis. South Med J. 2008;101:63–9.

    Article  Google Scholar 

  29. Mac Duff A, Grant AS. Critical care management of neuromuscular disease, including long term ventilation. Curr Opin Crit Care. 2003;9:106–12.

    Article  Google Scholar 

  30. Suzuki S, Utsugisawa K, Nagane Y, et al. Classification of myasthenia gravis based on autoantibody status. Arch Neurol. 2007;64:1121–4.

    Article  Google Scholar 

  31. Seybold ME. Treatment of myasthenia gravis. In: Engel AG, editor. Myasthenia gravis and myasthenic disorders, vol. 8. Oxford: Oxford University Press; 1999. p. 167–201.

    Google Scholar 

  32. Bedlack RS, Sanders DB. How to handle myasthenic crisis: essential steps in patient care. Postgrad Med J. 2000;107:211–2.

    Article  CAS  Google Scholar 

  33. Hickling KG, Walsh J, Henderson S, et al. Low mortality rate in adult respiratory distress syndrome using low-volume, pressure-limited ventilation with permissive hypercapnia: a prospective study. Crit Care Med. 1994;22:1568–78.

    Article  CAS  Google Scholar 

  34. Gadjos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997;41:789–96.

    Article  Google Scholar 

  35. Qureshi AI, Choudhry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment for myasthenic crisis. Neurology. 1999;52:629.

    Article  CAS  Google Scholar 

  36. Jani-Acsadi A, Lisak RP. Myasthenic crisis: guidelinea for prevention and treatment. J Neurol Sci. 2007;261:127–33.

    Article  Google Scholar 

  37. Pascuzzi RM, Coslette HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984;15:291–8.

    Article  CAS  Google Scholar 

  38. Ahmed S, Kirmani JF, Janjua N, et al. An update on myastheniccrisis. Curr Treat Options Neurol. 2005;7:129–41.

    Article  Google Scholar 

  39. Panda S, Goyal V, Behari M, et al. Myasthenic crisis: a retrospective study. Neurol India. 2004;52:453–6.

    CAS  PubMed  Google Scholar 

  40. Seneviratne J, Mandrekar J, Wijdicks EF, et al. Predictors of extubation failure in myasthenic crisis. Arch Neurol. 2008;65:929–33.

    PubMed  Google Scholar 

  41. Agarwal R, Aggarwal AN, Gupta D, et al. Low dose of snake antivenom is as effective as high dose in patients with severe neurotoxic snake envenomation. Emerg Med J. 2005;22:397–9.

    Article  CAS  Google Scholar 

  42. Sanmuganathan PS. Myasthenic syndrome of snake envenomation: a clinical and neurophysiological study. Postgrad Med J. 1998;74:596–9.

    Article  CAS  Google Scholar 

  43. Bomb BS, Roy S, Kumawat DC, et al. Do we need anti snake venom (ASV) for management of elapid ohitoxaemia? J Assoc Physicians India. 1996;44:31–3.

    CAS  PubMed  Google Scholar 

  44. Harsoor SS, Gurudatta CL, Balabhaskar S, et al. Ventilatory management of patients with neuroparalytic envenomation. Indian J Anaesth. 2006;50:452–5.

    Google Scholar 

  45. Eddleston M, Phillips MR. Self poisoning with pesticides. BMJ. 2004;328:42.

    Article  Google Scholar 

  46. Eyer P. The role of oximes in the management of organophosphorus pesticide poisoning. Toxicol Rev. 2003;22:165.

    Article  CAS  Google Scholar 

  47. Sidell FR. Soman and sarin: clinical manifestations and treatment of accidental poisoning by organophosphates. Clin Toxicol. 1974;7:1.

    Article  CAS  Google Scholar 

  48. Senanayake N, Karalliedde L. Neurotoxic effects of organophosphorus insecticides. An intermediate syndrome. N Engl J Med. 1987;316:761.

    Article  CAS  Google Scholar 

  49. Arrieta DE, Mccurdy SA, Henderson JD, et al. Normal range of human red cell acteylcholinesterase activity. Drug Chem Toxicol. 2009;32:182–5.

    Article  CAS  Google Scholar 

  50. Eddleston M, Roberts D, Buckley N. Management of severe organophosphorus pesticide poisoning. Crit Care. 2002;6:259.

    Article  Google Scholar 

  51. Tuovinen K. Organophosphate-induced convulsions and prevention of neuropathological damages. Toxicology. 2004;196:31.

    Article  CAS  Google Scholar 

  52. Streib EW. AAEE minimonograph #27: differential diagnosis of myotonic syndromes. Muscle Nerve. 1987;10:603–15.

    Article  CAS  Google Scholar 

  53. Fournier E, Arzel M, Sternberg D, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol. 2004;56:650–6.

    Article  CAS  Google Scholar 

  54. Levitt JO. Practical aspects in the management of hypokalemic periodic paralysis. J Transl Med. 2008;6:18.

    Article  Google Scholar 

  55. Griggs RC, Engel WK, Resnick JS. Acetazolamide treatment of hypokalemic periodic paralysis. Prevention of attacks and improvement of persistent weakness. Ann Intern Med. 1970;73:39–48.

    Article  CAS  Google Scholar 

  56. Hoskins B, Vroom FQ, Jarrell MA. Hyperkalemic periodic paralysis. Effects of potassium, exercise, glucose and acetazolamide on blood chemistry. Arch Neurol. 1975;32:519–23.

    Article  CAS  Google Scholar 

  57. Cho YS, Lim H, Kim SH. Comparison of lactated Ringer’s solution and 0.9% saline in the treatment of rhabdomyolysis induced by doxylamine intoxication. Emerg Med J. 2007;24:276–80.

    Article  Google Scholar 

  58. Ron D, Taitelman U, Michaelson M, et al. Prevention of acute renal failure in traumatic rhabdomyolysis. Arch Intern Med. 1984;144:277–80.

    Article  CAS  Google Scholar 

  59. Better OS, Rubinstein I, Winaver JM, et al. Mannitol therapy revisited (1940–1997). Kidney Int. 1997;52:886–94.

    Article  CAS  Google Scholar 

  60. Visweswaran P, Massin EK, Dubose TD Jr. Mannitol-induced acute renal failure. J Am Soc Nephrol. 1997;8:1028–33.

    CAS  PubMed  Google Scholar 

  61. Kellum JA. The use of diuretics and dopamine in acute renal failure: a systematic review of the evidence. Crit Care. 1997;1:53–9.

    Article  CAS  Google Scholar 

  62. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet. 2005;365:417–30.

    Article  CAS  Google Scholar 

  63. Vanholder R, Sever MS, Erek E, et al. Rhabdomyolysis. J Am Soc Nephrol. 2000;11:1553–61.

    CAS  PubMed  Google Scholar 

  64. Holt SG, Moore KP. Pathogenesis and treatment of renal dysfunction in rhabdomyolysis. Intensive Care Med. 2001;27:803–11.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Henry Ford Hospital and Wayne State University, Detroit, MI, USA

    Kavita Mohindra Grover & Naganand Sripathi

Authors
  1. Kavita Mohindra Grover
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naganand Sripathi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Neurology, All India Institute of Medical Sciences, New Delhi, India

    Mamta Bhushan Singh

  2. Department of Neurology, All India Institute of Medical Sciences, New Delhi, India

    Rohit Bhatia

Rights and permissions

Reprints and permissions

Copyright information

© 2019 The Author(s)

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Grover, K.M., Sripathi, N. (2019). Neuromuscular Emergencies. In: Singh, M., Bhatia, R. (eds) Emergencies in Neurology . Springer, Singapore. https://doi.org/10.1007/978-981-13-7381-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-7381-7_5

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-7379-4

  • Online ISBN: 978-981-13-7381-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation